Premium
Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression
Author(s) -
Luedke Dan,
McLaughlin Timothy T.,
Daughaday Carlos,
Luedke Susan,
Harrison Bruce,
Reed Garry,
Martello Orlando
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850201)55:3<542::aid-cncr2820550312>3.0.co;2-9
Subject(s) - vindesine , medicine , mitomycin c , vinca alkaloid , lung cancer , pulmonary toxicity , regimen , chemotherapy , toxicity , pulmonary function testing , anesthesia , surgery , vincristine , cyclophosphamide
A patient receiving mitomycin and vindesine chemotherapy for lung cancer developed abrupt onset of shortness of breath following vindesine administration. Pulmonary function tests both before and after rechallenging him with vindesine showed an acute obstructive pattern, which resolved with bronchodilator therapy; persisting lung damage was evident by arterial blood gas analysis. A record review of the 126 patients placed on the same chemotherapy regimen uncovered an additional 6 patients with possible lung toxicity. These seven patients (5.5%) had a variable clinical picture, from acute, reversible shortness of breath temporally related to vindesine administration to a progressive, fatal interstitial infiltrate. Physicians administering the combination of mitomycin and a vinca alkaloid should be aware of potential lung toxicity with variable clinical expression and be prepared to take appropriate action should they encounter it.